Acute interstitial lung disease in a patient with anaplastic lymphoma kinase-positive non-small-cell lung cancer after crizotinib therapy
Author:
Publisher
Oxford University Press (OUP)
Subject
Infectious Diseases,Microbiology,Parasitology
Link
http://academic.oup.com/omcr/article-pdf/2014/1/11/4417631/omu004.pdf
Reference8 articles.
1. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
2. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC
3. Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
4. Predictive Factors for Interstitial Lung Disease, Antitumor Response, and Survival in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib
5. Severe Acute Interstitial Lung Disease After Crizotinib Therapy in a Patient With EML4-ALK–Positive Non–Small-Cell Lung Cancer
Cited by 17 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A non-small cell lung carcinoma patient responded to crizotinib therapy after alectinib-induced interstitial lung disease;Journal of Zhejiang University (Medical Sciences);2023-10-01
2. Efficacy of crizotinib retreatment after crizotinib-related interstitial lung disease in a patient with ROS1-rearranged advanced lung adenocarcinoma: A case report and potential crizotinib retreatment strategy;Frontiers in Oncology;2022-10-18
3. Safety of lorlatinib following alectinib-induced pneumonitis in two patients with ALK-rearranged non-small cell lung cancer: a case series;Translational Lung Cancer Research;2021-01
4. Pulmonary complications of tyrosine kinase inhibitors and immune checkpoint inhibitors in patients with non-small cell lung cancer;Cancer Treatment and Research Communications;2021
5. Clinical characteristics and risk factors of drug‐induced lung injury by ALK tyrosine kinase inhibitors: A single center retrospective analysis;Thoracic Cancer;2020-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3